All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YF455 | Anti-IGF-1R×ERBB3 (Clone 5.7×Clone 2.3) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Clone 5.7 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF477 | Anti-IGF-1R×ERBB3 (M78×M7) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | M78 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF478 | Anti-IGF-1R×ERBB3 (SF×C8) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | SF | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF479 | Anti-IGF-1R×ERBB3 (P4×M1.3) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF480 | Anti-IGF-1R×ERBB3 (P4×C8) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF502 | Anti-IGF-1R×ERBB3 (Clone 5.7×Clone 2.3) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Clone 5.7 | Human | scFv (IGF-1R)-scFv (ERBB3)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF524 | Anti-IGF-1R×ERBB3 (M78×M7) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | M78 | Human | scFv (IGF-1R)-scFv (ERBB3)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF525 | Anti-IGF-1R×ERBB3 (SF×C8) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | SF | Human | scFv (IGF-1R)-scFv (ERBB3)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF526 | Anti-IGF-1R×ERBB3 (P4×M1.3) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF527 | Anti-IGF-1R×ERBB3 (P4×C8) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF596 | Anti-IGF-1R×ERBB3 (Clone 5.7×Clone 2.3) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Clone 5.7 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF618 | Anti-IGF-1R×ERBB3 (M78×M7) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | M78 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF619 | Anti-IGF-1R×ERBB3 (SF×C8) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | SF | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF620 | Anti-IGF-1R×ERBB3 (P4×M1.3) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF621 | Anti-IGF-1R×ERBB3 (P4×C8) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF643 | Anti-IGF-1R×ERBB3 (Clone 5.7×Clone 2.3) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | Clone 5.7 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF665 | Anti-IGF-1R×ERBB3 (M78×M7) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | M78 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF666 | Anti-IGF-1R×ERBB3 (SF×C8) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | SF | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF667 | Anti-IGF-1R×ERBB3 (P4×M1.3) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF668 | Anti-IGF-1R×ERBB3 (P4×C8) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | P4 | Human | scFv (IGF-1R)-scFv (ERBB3)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION